ASCO GU 2023 - Results from #160

Viewing 161-180 of 190 articles

ASCO GU 2023: Increased Utilization of Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy (PSMA-TRT) in African American (AA) Patients at an Academic Medical Center

ASCO GU 2023: 318: Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA

ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy

ASCO GU 2023: Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials

ASCO GU 2023: Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer

ASCO GU 2023: Machine-Learning to Predict Utility of Circulating Tumor DNA (ctDNA) for Somatic Genotyping

ASCO GU 2023: Cost-Effectiveness Analysis of Seven Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public Payer Perspective Using Network Meta-Analysis

ASCO GU 2023: Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC

ASCO GU 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual Patient Data Meta-Analysis from the MARCAP Consortium

ASCO GU 2023: Association of Intermittent vs Continuous Androgen Deprivation Therapy with Cardiovascular Disease and Endocrine/metabolic Disorders in Patients with Metastatic Prostate Cancer

ASCO GU 2023: Influence of Molecular Imaging on Patient Selection for Treatment Intensification Prior to Salvage Radiation Therapy for Prostate Cancer: A Post Hoc Analysis of the PROPS Trial

ASCO GU 2023: Best of the Journals: Prostate Cancer - Medical Oncology

ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic Hormone-Sensitive Prostate Cancer: Open-Label Single-Arm Study with an External Control Arm (ARASEC)

ASCO GU 2023: Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults with Metastatic Castration-Sensitive Prostate Cancer

ASCO GU 2023: Time Interval Between Radium‑223 Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study

ASCO GU 2023: Initial Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

ASCO GU 2023: Activity of Lutetium-177 PSMA (Lu-PSMA) and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Cabazitaxel: The PACAP Study

ASCO GU 2023: Evaluation of a Novel Transcriptomic Tumor Signature (PROSTest) as Response Biomarker for 177Lu-PSMA Therapy in Advanced Prostate Cancer

ASCO GU 2023: Best of the Journals: Prostate Cancer - Urologic Oncology

ASCO GU 2023: Impact of Run-in Treatment with Abiraterone Acetate and Prednisone in the MAGNITUDE Study of Niraparib and AAP in Patients with mCRPC and Homologous Recombination Repair Gene Alterations

1
2
3
4
5
6
7
8
9
10